SMMT

Summit Therapeutics Inc. (NASDAQ:SMMT) had a dazzling day of trading today as the company posted gains of nearly 200% to close Tueasday's trading. That massive win came after the company partnered with Hong Kong firm Akeso to license an antibody known as ivonescimab. Ivonescimab is a unique antibody that delivers multiple benefits for its users. Further, it's regarded as the most advanced in its field. The Food and Drug Administration in the United States has approved no antibodies like it. Additionally, the antibody won Breakthrough Therapy Designation status in China, providing further proof ot its capability.
https://www.tipranks.com/news/summit-therapeutics-explodes-up-on-licensing-deal?utm_source=advfn.com&utm_medium=referral